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Abstract
RPA is a single-stranded DNA binding protein that physically associates with the BLM complex. RPA stimulates BLM helicase
activity as well as the double Holliday junction dissolution activity of the BLM-topoisomerase IIIa complex. We investigated
the effect of RPA on the ssDNA decatenase activity of topoisomerase IIIa. We found that RPA and other ssDNA binding
proteins inhibit decatenation by topoisomerase IIIa. Complex formation between BLM, TopoIIIa, and RMI1 ablates inhibition
of decatenation by ssDNA binding proteins. Together, these data indicate that inhibition by RPA does not involve species-
specific interactions between RPA and BLM-TopoIIIa-RMI1, which contrasts with RPA modulation of double Holliday
junction dissolution. We propose that topoisomerase IIIa and RPA compete to bind to single-stranded regions of catenanes.
Interactions with BLM and RMI1 enhance toposiomerase IIIa activity, promoting decatenation in the presence of RPA.
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Introduction
BLM is a member of the RecQ family of helicases that
safeguards genome integrity [1]. Bi-allelic mutations in the BLM
gene give rise to Bloom syndrome, a rare cancer predisposition
disorder in humans [2]. The BLM core complex, composed of
BLM, DNA topoisomerase IIIa (TopoIIIa), and RMI1, is a
suppressor of illegitimate recombination [3]. This complex
catalyses a remarkable dissolution reaction that leads to the
dissociation of DNA structures containing two Holliday junctions
into genetically silent non-crossover products [4–8]. The double
Holliday junction (DHJ) dissolution reaction consists of two
enzymatic steps: 1) branch migration of two Holliday junctions
towards each other by the helicase activity of BLM and the
relaxation activity of TopoIIIa, resulting in two duplex DNAs
interlinked via catenated single strands, and 2) unlinking of the
resulting structure, termed a hemicatenane, by the decatenase
activity of TopoIIIa [4,9]. Because DHJs resemble intermediates
that arise from the process of homologous recombination, the
dissolution activity of BLM-TopoIIIa-RMI1 provides a clear
explanation of why cells from BS patients exhibit genetic instability
associated with elevated levels of sister-chromatid exchanges
[4,10,11].
Replication Protein A (RPA) is a single-stranded DNA (ssDNA)
binding protein that is indispensable in all eukaryotes [12]. RPA
plays essential roles in many aspects of DNA metabolism processes
including DNA replication, DNA repair, recombination, and
DNA damage checkpoint signaling [13]. RPA homologs, which
are highly conserved among eukaryotic organisms [14], are
heterotrimeric complexes composed of subunits of 70-, 32-, and
14-kDa in size [15,16]. Members of this family bind non-
specifically to single-stranded DNA with high affinity via four
conserved oligonucleotide-binding folds (OB-folds) [17]. The
binding of ssDNA by RPA follows a hierarchical assembly
pathway in which OB-folds bind sequentially from the 59 to 39
direction on ssDNA [17]. Naked ssDNA is a source of genome
instability because of its tendency to form secondary structures and
its susceptibility to nucleolytic cleavage [18,19]. Therefore, RPA
maintains genome integrity by binding to and protecting ssDNA
until DNA metabolism processes are complete.
RPA associates with the BLM complex. RPA co-immunopre-
cipitates with BLM and RMI1 [20,21] and specifically stimulates
the DHJ dissolution activity of BLM-TopoIIIa [5]. RPA directly
interacts with BLM helicase via its 70 kDa subunit in a manner
that is independent of DNA [22]. RPA inhibits BLM strand-
annealing activity while specifically stimulating BLM helicase
activity to unwind long stretches of duplex DNA [22,23]. The
stimulation requires the physical interaction between BLM and
RPA [24], and is diminished when RPA is replaced with E. coli
SSB (Single-stranded Binding Protein) (EcSSB) [25]. Therefore,
RPA enhances BLM activity to unwind double-stranded DNA by
two distinct mechanisms; RPA not only passively prevents the re-
annealing of unwound ssDNA, but also actively promotes duplex
DNA unwinding via a direct protein-protein interaction. Togeth-
er, these data argue that the stimulation of DHJ dissolution by
RPA is in part due to the specific stimulation of BLM helicase
activity.
In this study, we investigated whether RPA modulates the
second step of the dissolution reaction, the decatenation by
TopoIIIa. Using a previously established in vitro system that
mimics the latest stage in DHJ dissolution [26] we found that RPA
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inhibits TopoIIIa decatenase activity. RPA inhibition occurs non-
specifically since EcSSB also inhibits TopoIIIa decatenase activity.
Interestingly, BLM alleviates the inhibition of TopoIIIa decate-
nase activity by either RPA or EcSSB. However, BLM does not
alleviate the inhibition of EcTop1 decatenase activity by EcSSB or
RPA, suggesting that the specific interaction between BLM and
TopoIIIa, but not between TopoIIIa and RPA, is crucial for
TopoIIIa action on RPA- (or EcSSB-) coated single-stranded
DNA substrates. Together, these data indicate the complex nature
of the interplay among BLM core complex members during the
steps of DHJ dissolution.
Results
RPA inhibits TopoIIIa decatenase activity
Because RPA positively regulates BLM-TopoIIIa-mediated
DHJ dissolution [5], we asked whether RPA stimulates TopoIIIa
decatenase activity. We found that TopoIIIa decatenase activity
was inhibited by RPA, in a concentration dependent manner, by
almost 10-fold (Figure 1A). Both TopoIIIa and E. coli topoisom-
erase I (EcTop1) belong to type IA family of topoisomerases [27].
To test the specificity of RPA inhibition, we tested the ability of
RPA to inhibit EcTop1-mediated decatenation. We found that
RPA reduced EcTop1-mediated decatenation at a level similar to
that seen for TopoIIIa-mediated decatenation (Figure 1B). To-
gether, these data indicate that RPA inhibits decatenation by type
Figure 1. RPA inhibits the decatenase activity of both TopoIIIa
and EcTop1. (A) Decatenation reactions containing TopoIIIa (30 nM,
lanes 2–4) and RPA (100 nM, lane 3; 200 nM, lanes 4 and 5) as indicated
were fractionated on a denaturing polyacrylamide gel and autoradio-
graphed. Quantification of the decatenation products is presented in
the histogram, normalized to the reactions in lane 2 (TopoIIIa alone).
The percent of catenated substrate converted to circular products is
indicated. (B) Decatenation reactions containing EcTop1 (6 nM, lanes 2–
4) and RPA (100 nM, lane 3; 200 nM, lanes 4 and 5) as indicated were
fractionated on a denaturing polyacrylamide gel and autoradiographed.
Quantification of the decatenation products is presented in the
histogram, normalized to the reactions in lane 2 (EcTop1 alone). The
percent of catenated substrate converted to circular products is
indicated.
doi:10.1371/journal.pone.0041208.g001
Figure 2. EcSSB inhibits the decatenase activity of both
TopoIIIa and EcTop1. (A) Decatenation reactions containing TopoIIIa
(30 nM, lanes 2–4), EcTop1 (6 nM, lanes 5–7) and EcSSB (100 nM, lanes 3
and 6; 200 nM, lanes 4, 7 and 8) as indicated were fractionated on a
denaturing polyacrylamide gel and autoradiographed. Quantification of
the decatenation products is presented in the histogram, normalized to
the reactions in lane 2 (TopoIIIa alone) or lane 5 (EcTop1 alone). The
percent of catenated substrate converted to circular products is
indicated. (B) Decatenation reactions containing TopoIIIa (30 nM, lanes
2–5) and EcSSB (0.4 mM, lane 3; 0.8 mM, lane 4; 3.2 mM, lane 5) as
indicated were fractionated on a denaturing polyacrylamide gel and
autoradiographed. Quantification of the decatenation products is
presented in the histogram, normalized to the reactions in lane 2
(TopoIIIa alone). The percent of catenated substrate converted to
circular products is indicated.
doi:10.1371/journal.pone.0041208.g002
RPA Inhibition of TopoIIIa Decatenase Activity
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IA topoisomerases, and that the inhibition is likely independent of
RPA-topoisomerase interactions.
EcSSB also inhibits TopoIIIa decatenase activity
Since RPA inhibits the decatenase activities from both TopoIIIa
and EcTop1, we next asked whether EcSSB, the RPA functional
homolog in E. coli, inhibits decatenation. We incubated single-
stranded catenanes with TopoIIIa or EcTop1 at concentrations at
which both enzymes exhibited similar decatenase activities
(Figure 2A, lane 2 versus lane 5). Upon the addition of 100 to
200 nM EcSSB to the reactions, we found that EcSSB readily
inhibited EcTop1 decatenase activity by more than 4-fold
(Figure 2A, lanes 6 and 7 versus lane 5). On the other hand,
EcSSB at the same concentrations reduced the TopoIIIa-
mediated decatenation by only 33% (Figure 2A, lanes 3 and 4
versus lane 2). Strong inhibition of TopoIIIa decatenase activity
was finally achieved at 3.2 mM of EcSSB (versus 100 nM to
inhibit EcTop1 activity) (Figure 2B). Thus, unlike RPA, EcSSB
only efficiently inhibits the decatenase activity of EcTop1, its
cognate topoisomerase. The discrepancy between the efficiency of
EcSSB inhibition in each case is more likely to arise from the
difference in substrate binding affinities between TopoIIIa and
EcTop1, rather than as a consequence of species specific
interactions, because EcTop1 and EcSSB do not physically
interact with each other [28].
BLM-RMI1 alleviates RPA inhibition of TopoIIIa
decatenase activity
Since BLM and RMI1 stimulate TopoIIIa decatenase activity
[26], we asked whether BLM or RMI1 alleviates RPA inhibition of
TopoIIIa decatenase activity. When performing the alleviation
experiment, we incubated RPA alone with single-stranded
catenanes for five minutes before adding BLM, TopoIIIa or
RMI1 to investigate the ability of the complex to interact with
RPA-coated substrates. Interestingly, not only did BLM restore
TopoIIIa activity in the presence of RPA, it also further stimulated
the decatenase activity by 1.5-fold (Figure 3A, lanes 4 and 5 versus
lane 2 and 3), indicating that BLM alleviates RPA inhibition of
TopoIIIa-mediated decatenation. In contrast, RMI1 did not
alleviate RPA inhibition (Figure 3A, lanes 6 and 7 versus lane 3).
The lack of alleviation by RMI1 was not due to insufficient RMI1
because RMI1 at similar concentrations stimulates TopoIIIa-
mediated decatenation by 2-fold in the absence of RPA [26].
Figure 3. BLM-RMI1 alleviates RPA inhibition of TopoIIIa
decatenase activity. (A) Decatenation reactions containing TopoIIIa
(30 nM, lanes 2–7), RPA (100 nM, lanes 3–8), BLM (33 nM, lane 4; 66 nM,
lanes 5 and 9) and RMI1 (100 nM, lane 6; 200 nM, lanes 7 and 10) as
indicated were fractionated on a denaturing polyacrylamide gel and
autoradiographed. Quantification of the decatenation products is
presented in the histogram, normalized to the reactions in lane 2
(TopoIIIa alone). The percent of catenated substrate converted to
circular products is indicated. (B) Decatenation reactions containing
TopoIIIa (15 nM, lanes 2–8), RPA (100 nM, lanes 3–6, 8 and 9), BLM
(17 nM, lanes 4–9), wild type RMI1 (75 nM, lane 5; 150 nM, lanes 6, 7
and 9) and RMI1-LLTD mutant (150 nM, lanes 8 and 10) as indicated
were fractionated on a denaturing polyacrylamide gel and autoradio-
graphed. Quantification of the decatenation products is presented in
the histogram, normalized to the reactions in lane 2 (TopoIIIa alone).
The percent of catenated substrate converted to circular products is
indicated. (C) Decatenation reactions containing TopoIIIa (7.5 nM, lanes
2–4), BLM (8 nM, lanes 2–4), RMI1 (38 nM, lanes 2–4) and RPA (140 nM,
lane 3; 280 nM, lane 4) as indicated were fractionated on a denaturing
polyacrylamide gel and autoradiographed. Quantification of the
decatenation products is presented in the histogram, normalized to
the reactions in lane 2 (TopoIIIa-BLM-RMI1). The percent of catenated
substrate converted to circular products is indicated.
doi:10.1371/journal.pone.0041208.g003
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Together, these data indicate that BLM, but not RMI1, restores
TopoIIIa decatenase activity in the presence of RPA.
BLM and RMI1 synergistically stimulate TopoIIIa decatenase
activity [26]. We explored the possibility that BLM and RMI1
synergistically alleviate RPA inhibition of TopoIIIa decatenation.
We found that the addition of both BLM and RMI1 stimulated
TopoIIIa-mediated decatenation by a remarkable ,30-fold even
in the presence of RPA (Figure 3B, lane 5 versus lanes 2 and 3).
The synergistic stimulation observed here (Figure 3B, lane 5) likely
reflected the maximum decatenation achievable because an
increase in RMI1 concentration (Figure 3B, lane 6 versus lane
5), or the absence of RPA in reaction mixture (Figure 3B, lane 7
versus lane 6) did not further stimulate decatenation.
Alanine mutations at the conserved Leu-Leu-Thr-Asp (-LLTD)
residues of RMI1 disrupt the interaction between RMI1 and
TopoIIIa and ablate the stimulation of TopoIIIa decatenase
activity by BLM [26]. Similarly, we found that RMI1-LLTD
mutant in the presence of BLM failed to restore TopoIIIa
decatenase activity above the level seen with BLM alone
(Figure 3B, lane 8 versus lane 4). Therefore, even in the presence
of RPA, the synergistic stimulation requires the physical interac-
tion between RMI1 and TopoIIIa.
RPA negatively regulates the decatenase activity of
TopoIIIa-BLM-RMI1
RPA, a core member of the BLM complex, specifically
stimulates BLM helicase activity [23–25]. Therefore, although
RPA alone negatively regulates TopoIIIa decatenase activity, it is
conceivable that RPA stimulates decatenation by TopoIIIa
together with BLM and RMI1 when all members of the BLM
core complex are present. To test this possibility, we set up
reactions containing BLM, TopoIIIa, and RMI1 at concentrations
that did not produce the maximum decatenation in order to
capture potential stimulation by RPA. We found that instead of
stimulating the activity of the complex, RPA inhibited decatena-
tion by BLM-TopoIIIa-RMI1, in a concentration dependent
manner, by more than 3-fold (Figure 3C, lanes 3 and 4 versus lane
2). These data indicate that RPA negatively regulates TopoIIIa
decatenase activity even in the presence of BLM and RMI1.
BLM alleviates EcSSB inhibition of TopoIIIa, but not of
EcTop1, decatenase activity
Since EcSSB inhibits TopoIIIa decatenase activity, we asked
whether BLM and RMI1 alleviate EcSSB-mediated inhibition of
Figure 4. BLM alleviates EcSSB inhibition of TopoIIIa, but not
EcTop1, decatenase activity. (A) Decatenation reactions containing
TopoIIIa (30 nM, lanes 2–8), EcSSB (3.2 mM, lanes 3–9), BLM (33 nM,
lanes 4, 8 and 9; 66 nM, lane 5) and RMI1 (100 nM, lanes 6, 8 and 9;
200 nM, lane 7) as indicated were fractionated on a denaturing
polyacrylamide gel and autoradiographed. Quantification of the
decatenation products is presented in the histogram, normalized to
the reactions in lane 2 (TopoIIIa alone). The percent of catenated
substrate converted to circular products is indicated. (B) Decatenation
reactions containing TopoIIIa (20 nM, lanes 2–9), RPA (200 nM, lanes 3–
5 and 10), EcSSB (3.2 mM, lanes 6–8 and 10) and BLM (33 nM, lanes 4
and 7; 66 nM, lanes 5 and 8–10) as indicated were fractionated on a
denaturing polyacrylamide gel and autoradiographed. Quantification of
the decatenation products is presented in the histogram, normalized to
the reactions in lane 2 (TopoIIIa alone). The percent of catenated
substrate converted to circular products is indicated. (C) Decatenation
reactions containing EcTop1 (6 nM, lanes 2–7), EcSSB (100 nM, lanes 3–
6 and 8), BLM (17 nM, lanes 4–8) and RMI1 (75 nM, lane 5; 150 nM, lanes
6–8) as indicated were fractionated on a denaturing polyacrylamide gel
and autoradiographed. Quantification of the decatenation products is
presented in the histogram, normalized to the reactions in lane 2
(EcTop1 alone). The percent of catenated substrate converted to
circular products is indicated.
doi:10.1371/journal.pone.0041208.g004
RPA Inhibition of TopoIIIa Decatenase Activity
PLoS ONE | www.plosone.org 4 July 2012 | Volume 7 | Issue 7 | e41208
TopoIIIa decatenation. We found that BLM, but not RMI1,
alleviated the inhibition of TopoIIIa decatenation by EcSSB
(Figure 4A, lanes 4 and 5 versus lanes 6 and 7). The addition of
RMI1 to a reaction containing BLM and TopoIIIa caused a
synergistic stimulation of decatenation even in the presence of
excess EcSSB (Figure 4A, lane 8 versus lane 2 and 3). These data
indicate that BLM, in concert with RMI1, alleviates EcSSB
inhibition of TopoIIIa decatenase activity, as was the case with
RPA inhibition.
To assess the relative activity of BLM in alleviating RPA or
EcSSB inhibition, we monitored decatenation in reactions
containing either RPA or EcSSB at concentrations that reduced
TopoIIIa decatenase activity to similar levels (Figure 4B, lane 3
versus lane 6). By titrating BLM into the reaction mixtures, we
found that BLM restored TopoIIIa decatenase activity to similar
levels regardless of whether the activity was inhibited by RPA or
EcSSB (Figure 4B, lane 4 and 5 versus lane 7 and 8). Decatenation
by BLM-TopoIIIa was further enhanced when RPA or EcSSB
was removed from the reaction (Figure 4B, lane 9 versus lanes 5
and 8). Therefore, although BLM physically interacts with RPA
[22,24], but not EcSSB, the finding that BLM relieves the RPA-
and EcSSB-mediated inhibition at similar levels indicates that the
BLM alleviation does not require physical interaction between
BLM and RPA.
We next tested the ability of BLM and RMI1 to restore
EcTop1-mediated decatenation in the presence of EcSSB inhibi-
tion. We have shown previously that BLM mildly stimulates
EcTop1 decatenase activity, although the two proteins lack direct
physical interaction [26]. RMI1, on the other hand, does not
stimulate EcTop1 [26]. We found that the level of EcTop1-
mediated decatenation in the presence of EcSSB inhibition
remained unaffected by the addition of BLM and RMI1
(Figure 4C, lanes 4–6 versus lane 3). As a positive control to show
that the enzymes were active, BLM and RMI1 stimulated
EcTop1-mediated decatenation when the substrates were not
pre-coated with EcSSB (Figure 4C, lane 7 versus lane 2).
Therefore, unlike the situation with TopoIIIa, BLM is unable to
restore EcTop1 decatenase activity in the presence of EcSSB.
Discussion
In this study, we showed that RPA non-specifically inhibits
decatenation by TopoIIIa. Such inhibition is alleviated by BLM
and RMI1. BLM alleviates RPA inhibition via a mechanism that is
independent of BLM-RPA interaction. These findings contrast
with previous demonstrations that BLM physically interacts with
RPA [22] and that the interaction is important for the optimal
strand-passage activity of BLM-TopoIIIa [5].
Previous studies have shown that RPA positively regulates BLM
helicase activity [22,23] and BLM-TopoIIIa dissolution activity
[5]. Interestingly, we found that RPA inhibits TopoIIIa decate-
nase activity at a TopoIIIa:RPA stoichiometry near 1:1. We
envisage two possible scenarios for RPA inhibition. First, since
RPA physically associates with BLM-TopoIIIa-RMI1 [20,21], the
inhibition could be mediated via direct interaction between RPA
and TopoIIIa causing conformational changes in TopoIIIa that
reduce its catalytic activity. Alternatively, binding of RPA to
ssDNA catenanes could exclude TopoIIIa from RPA-coated
substrates, thereby eliminating decatenation. Although the two
scenarios are not mutually exclusive, we favor the latter for three
reasons. First, like RPA, TopoIIIa recognizes and interacts with
single-stranded DNA [29,30]. Exposed single-stranded regions
within DNA substrates greatly enhance the DNA relaxation
activity of type 1A topoisomerases, including TopoIIIa [30–32].
Second, even though EcSSB and EcTop1 lack physical interac-
tions, an excess molar ratio of EcSSB disrupts EcTop1-DNA
complex formation and inhibits EcTop1-mediated DNA relaxa-
tion [28] and decatenation (this study). Last, RPA readily inhibits
the decatenase activity of EcTop1, the TopoIIIa homolog in E.
coli, suggesting that the RPA inhibition is non-specific. We propose
a competitive binding model in which RPA inhibits TopoIIIa
decatenation by binding to the substrates and eliminating the
access of TopoIIIa to ssDNA regions, a mechanism that is
independent of direct protein-protein interaction between the
topoisomerase and the ssDNA binding protein (Figure 5A).
The inhibition of TopoIIIa decatenase activity by RPA is
intriguing given that RPA positively regulates the dissolution
activity of BLM and TopoIIIa [5]. One explanation for this
discrepancy is that RPA inhibition is abrogated in the presence of
BLM. Indeed, BLM readily alleviated the RPA-mediated inhibi-
Figure 5. TopoIIIa, BLM and RMI1 cooperate to catalyze decatenation on RPA-coated single-stranded catenane. (A) In a competitive
binding model, TopoIIIa alone is unable to access RPA-coated substrate. (B) Complex formation by BLM, TopoIIIa, and RMI1 enables displacement of
RPA from the substrate. (C) Alternatively, the DNA binding activity of BLM drives the complex to the substrate even when the substrate is coated with
RPA, promoting decatenation.
doi:10.1371/journal.pone.0041208.g005
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tion of TopoIIIa decatenase activity. Furthermore, BLM also
alleviated EcSSB-mediated inhibition, suggesting that the allevi-
ation does not require direct BLM-RPA interaction. The non-
specific nature of the inhibition (i.e., that it occurs with either RPA
or EcSSB) suggests a model of alleviation in which BLM-TopoIIIa
simply displaces RPA or EcSSB from the catenane (Figure 5B). On
the other hand, BLM did not relieve inhibition of E. coli TopI by
EcSSB, indicating that the cognate RecQ-helicase/type IA
topoisomerase pair is important for decatenation in the presence
of ssDNA binding proteins. BLM shows high affinity for various
DNA structures, including the fork structure present in single-
stranded catenanes [33,34]. Therefore, the DNA binding activity
of BLM could drive the BLM-TopoIIIa-RMI1 complex to the
substrate, making substrate recognition by TopoIIIa unnecessary
in the presence of RPA or EcSSB. Then, the enhanced decatenase
activity of the BLM-TopoIIIa-RMI1 complex would overcome
RPA or EcSSB inhibition (Figure 5C). As is the case with a naked
ssDNA catenane [26], optimal decatenation of RPA-coated
catenanes is achieved when all three members of the BLM-
TopoIIIa-RMI1 complex are present.
Materials and Methods
Proteins
TopoIIIa and RMI1 were purified as described [26,35]. BLM
was a gift from Ian Hickson (University of Copenhagen). EcTop1
(M0301S) was purchased from New England BioLabs. RPA was
purchased from Enzo Life Science (ALX-201-296). EcSSB was
purchased from Epicentre Biotechnologies (SSB02200).
Single-stranded DNA decatenation assay
Single-stranded DNA decatenation assay were performed as
described [26]. Briefly, purified single-stranded catenane
(400 fmol) was incubated with the indicated proteins in 15 ml of
reaction buffer containing 50 mM Tris-HCl (pH 7.5), 40 mM
NaCl, 5 mM MgCl2, 1 mM DTT, and 0.1 mg/ml BSA at 37uC
for 30 minutes. For reactions containing BLM, 5 mM ATP was
added to initiate the reactions because the stimulation of TopoIIIa
decatenase activity by BLM requires ATP [26]. For the alleviation
of RPA/EcSSB inhibition experiments, RPA (or EcSSB) was
incubated with single-stranded catenane at 37uC for 5 minutes
before the addition of the rest of the components at 37uC for
another 30 minutes.
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